We also demonstrated that the inhibition of vimentin with the recently developed inhibitor FiVe1 led to a significant sensitization of ovarian cancer cells to cisplatin and to a reversal of resistance in the cisplatin-resistant cell line. This evidence concerns the gene VIM and ovarian cancer.